Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.66 |
| ▸ | NPC1 | O15118 | 11/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.62 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | PTGES | O14684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31423384 | 0.85 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2HTTKMT2A | |
| SCHEMBL30387733 | 0.81 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2HTTKMT2A | |
| SCHEMBL3775117 | 0.80 | ALDH1A1 (0.71) | SMN1; SMN2KCNK3KCNK9PTGESMAPT | |
| SCHEMBL30300523 | 0.79 | NPC1 (0.73) | RAB9ANPC1SMN1; SMN2HTTKMT2A | |
| SCHEMBL1380178 | 0.78 | NPC1 (0.54) | RAB9ANPC1SMN1; SMN2HTTKMT2A | |
| SCHEMBL3778242 | 0.78 | KCNK3 (0.61) | RAB9ANPC1KCNK3KCNK9KMT2A | |
| SCHEMBL5801648 | 0.78 | TRPV1 (0.57) | RAB9ANPC1SMN1; SMN2HTTKCNK3 | |
| SCHEMBL3766556 | 0.77 | KCNK3 (0.82) | RAB9ANPC1SMN1; SMN2HTTKCNK3 | |
| SCHEMBL3778087 | 0.77 | KCNK3 (0.69) | RAB9ANPC1SMN1; SMN2HTTKCNK3 | |
| SCHEMBL3779837 | 0.76 | PTGES (0.69) | RAB9ANPC1KCNK3KCNK9PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | claimed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
| WO-2009103778-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | IL1B, LITAF, CYP11B1 | RAB9A 2083/4885NPC1 145/4885SMN1; SMN2 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.